APA (7th ed.) Citation

Saliby, R., Xie, W., Wells, J., Saad, E., Eid, M., Semaan, K., . . . Choueiri, T. (2024). 1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study. Annals of Oncology, 35, S1021. https://doi.org/10.1016/j.annonc.2024.08.1797

Chicago Style (17th ed.) Citation

Saliby, R.M, et al. "1704P Potential Surrogate Endpoints for Overall Survival (OS) in Immunotherapy (IO)-treated Metastatic Renal Cell Carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) Study." Annals of Oncology 35 (2024): S1021. https://doi.org/10.1016/j.annonc.2024.08.1797.

MLA (9th ed.) Citation

Saliby, R.M, et al. "1704P Potential Surrogate Endpoints for Overall Survival (OS) in Immunotherapy (IO)-treated Metastatic Renal Cell Carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) Study." Annals of Oncology, vol. 35, 2024, p. S1021, https://doi.org/10.1016/j.annonc.2024.08.1797.